
    
      This study was an open label, balanced, randomized, two-treatment, two-period, two-sequence,
      single dose crossover bioavailability study planned on 40 healthy, adult, human subjects
      under fed conditions.

      A total of forty (40) healthy, adult, human subjects were admitted in the study to allow the
      dosing in the first period. Out of the forty subjects, only thirty eight (38) subjects
      completed both the periods of the study.
    
  